Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon®


Cite item

Full Text

Abstract

A pilot trial has been performed to assess effects of permixon on
prostatic tissue in patients with benign prostatic hyperplasia (BPH).
A total of 49 BPH and control patients entered the trial. 36 patients
of the study group were randomized into 3 subgroups of 12 patients
each. Permixon was taken in a standard dose of 320 mg/day for 3, 6
and 12 months, respectively. Mean duration of BPH was 3.7 years
(0-8 years). Mean value of PCA was 6.0 ng/ml. The control group of
13 patients were not given permixon. Multifocal prostatic biopsy was
performed in all the patients before and after the treatment or follow-up.
Stromal-parenchymatous correlation in the study group significantly
increased (by 59%) - from 3.28 (0.25-9.61) to 5.22 (1.20-10.67)
(p = 0.0002). For the control group this correlation was insignificant.
Permixon-treated patients demonstrated inhibition of prostatic epithelium
proliferative activity by 32% (p = 0.0001) and a rise in the
stage of proliferative centers development from stage II-III to IV-V.
Intensity of inflammation in prostatic tissue decreased by 53% in the
study group and insignificantly in the control group. Thus, permixon
treatment of BPH leads to a significant rise in stromal-parenchymatous
correlation due to inhibition of proliferative activity of prostatic
epithelium and attenuation of inflammation.

References

  1. Buck А. С. Phytotherapy for the prostate. Br. J. Urol. 1996; 78: 325-336.
  2. Сивков А. В. Пермиксон: механизм действия, клиническая эффективность и место в лечении ДГПЖ. В кн.: Лопаткин Н. А. (ред.) Доброкачественная гиперплазия предстательной железы. М.; 1999. 117-133.
  3. Carraro J. С., Raynaud J. R., Koch G. et al. Comparison of phytotherapy (Permixon) with finasteride in treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients. Prostate 1996; 29: 231.
  4. Debruyne F. on behalf of the PERMAL sytudy Group. Comparison of a phytotherapeutic agent (Permixon) with an alphablocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study. In: Materials of 17-th European Association of Urology Meeting. Birmingham; 2002; CD: A-424.
  5. Алиев Ю. Г., Винаров А. З., Локшин К., Л., Спивак Л. Г. Пятилетний опыт лечения пермиксоном (Serenoa repens, "Pierre Fabre Medicament") больных гиперплазией простаты. Урология 2002; 1: 23-25.
  6. Пытель Ю. А., Лопаткин Н. А., Гориловский Л. М. и др. Результаты долгосрочного применения пермиксона у больных с симптомами нарушения функции нижних мочевых путей, обусловленными доброкачественной гиперплазией предстательной железы. Урология 2004; 2: 3-7.
  7. Boyle P., Robertson С., Lowe F. С., Roehrborn С. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55 (4): 533-539
  8. Wilt T. J. Phytotherapy. In: Chappie С. R., McConnell J. D.,Tubaro A. Benign prostatic hyperplasia. Current therapy. Martin Dunitz; 2000. 39-56.
  9. Wilt T. J., Ishani A., Stark G. et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev 2000- 01- 2, CD 001423.
  10. Ваупе С. W., Donnelly F., Ross M., Habib F. K. Serenoa repens (Permixon): a 5@a-reductase types I and II inhibitor - new evidence in a coculture model of BPH. Prostate 1999' 40' 232- 241.
  11. Ваупе С. W., Ross M., Donnelly F., Habib F. K. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J. Urol. (Baltimore) 2000; 164 (3, pt 1): 876-881.
  12. Habib F., Ross M. Why does the lipido-sterolic extract of Serenoa repens Permixon fail to inhibit prostate specific antigen whilst maintaining its 5 alpha reductase inhibitory activity in the human prostate. In: Materials of 18-th European Association of Urology Meeting. Madrid; 2003; CD: A-71.
  13. Di Silverio F., D'Eramo G., Lubrano С. et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostate tissue of benign prostatic hypertrophy. Eur. Urol. 1992; 21: 309-314.
  14. Van Coppenolle F., Le Bourhis X., Carpentier F. et al. Pharmacological effects of lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000; 43 (1): 49-58.
  15. Baker M. Inflammation, vascularisation, and benign prostatic hyperplasia. In: 6-th Congress of the Mediterranean Association of Urology: Materials of Satellite Symposium. Cairo; 1999. 20- 22.
  16. Sciarra A. About the role of growth factors in BPH. In: 6-th Congress of the Mediterranean Association of Urology. Materials of Satellite Symposium. Cairo; 1999. 12-16.
  17. Marks L. S., Epstein J. I., Partin A. W. et al. Effects of saw palmetto herbal blend in men with symtpomatic benign prostatic hyperplasia. J. Urol. (Baltimore) 2000; 163 (5): 1451-1456.
  18. Vacherot F., Azzouz M., Gil Diez S. et al. Induction of apoptosis and inhibition of proliferation by Permixon in benign prostatic hyperplasia. Prostate 2000; 45: 259-266.
  19. Buck C., More L., Mahendra V. The inhibition of nephrocalcinosis in an animal model with the lipido-sterolic extract of Serenoa repens, Permixon. In: Materials of 17-th European Association of Urology Meeting. Birmingham; 2002; CD: A-317.
  20. Reissigl A., Pointner J., Djavan B. et al. Multicentre study to evaluate the safety and efficacy of phytotherapeuticum Permixon in the treatment of chronic prostatitis / chronic pelvic pain syndrome. In: Materials of 18-th European Association of Urology Meeting. Madrid; 2003; CD: A-49.
  21. Vela-Navarrete R., Garcia-Cardoso J., Barat A. et al. Effects of the lipido sterolic extract of Serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients. In: Materials of 17-th European Association of Urology Meeting. Birmingham; 2002; CD: A-238.
  22. Paubert-Braquet M., Richardson F. O., Servent-Saez N. et al. Effect of Serenoa repens extract (Permixon) on estradiol: testosterone-induced experimental prostate enlargement in the rat. Pharmacol. Res. 1996; 34 (3/4): 171-179.
  23. Di Silverio F., Monti S., Sciarra A. et al. Effects of long term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37 (2): 77-83.
  24. Ragab A., Ragab-Thomas J. M. F., Delhon A. et al. Effects of Permixon (Sereprostat in Spain) on phospholipase A2 activity and arachidonic acid metabolism in cultured prostatic cells. In:
  25. Di Silverio F., Steg A., eds. New trends in bladder cancer chemotherapy. New trends in BPH etiopathogenesis: Proceedings of the International Workshop in Urology, 1987, Jul. 22-25, Cannes. Rome: Acta Medica; 1988. 239-296.
  26. Paubert-Braquet M., Mencia Huerta J. M., Cousse H. et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostagland. Leukotr. Essent. Fatty Acids 1997; 57 (3): 299-304.
  27. Tarayre J. P., Delhon A., Lauressergues H. et al. Action antoedemateuse d'un extrait hexanique de drupes de Serenoa repens Bartr. Ann. Pharm. Franc. 1983; 41 (6): 559-570.
  28. Медведев А. А. Экстракты Serenoa repens в лечении больных доброкачественной гиперплазией предстательной железы: Автореф. дис. ... канд. мед. наук. М.; 2001.
  29. Лопаткин Н. А. (ред.) Руководство по урологии. М.: Медицина; 1998; т. 3: 368-522.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies